Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Novartis Secures Exclusive Rights to Zonsen PepLib’s Radioligand Asset

Fineline Cube Jan 12, 2026
Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Fineline Cube Jan 11, 2026
Company Deals

Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push

Fineline Cube Jan 11, 2026
Company Deals

Takeda Licenses Halozyme’s ENHANZE Technology for Vedolizumab in Global Deal

Fineline Cube Jan 11, 2026
Company Deals

Eisai China and Xuanwu Hospital Forge Strategic Cooperation for Drug R&D

Fineline Cube Jan 11, 2026
Policy / Regulatory

NMPA Issues New Rules to Strengthen Pharmaceutical Contract Manufacturing Oversight

Fineline Cube Jan 9, 2026
Company Drug

Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets

Fineline Cube Jan 12, 2026
Company Drug

Genrix Bio’s GR1803 NDA Accepted for BCMA-Targeted Multiple Myeloma Therapy

Fineline Cube Jan 11, 2026
Company Medical Device

Sinovation Medical’s SinoLITT System and Fiber Kit Gain NMPA Approval for Epilepsy Treatment

Fineline Cube Apr 18, 2023

Sinovation (Beijing) Medical Technology Co., Ltd has announced that its in-house developed magnetic resonance monitoring...

Company R&D

Merck and XtalPi Leverage Molecular Dynamics to Enhance Small-Molecule Crystallization

Fineline Cube Apr 17, 2023

German pharmaceutical giant Merck (NYSE: MRK) and China-based drug discovery solutions specialist XtalPi have published...

Company Drug

Neurophth Biotechnology Receives NMPA Approval for Phase I/II Gene Therapy Study

Fineline Cube Apr 17, 2023

Neurophth Biotechnology Ltd, a leading gene therapy specialist based in China, has announced that it...

Company Deals

Shenzhen Core Medical Technology Secures RMB 200 Million in Series C+ Financing for Artificial Heart Tech

Fineline Cube Apr 17, 2023

Shenzhen Core Medical Technology Co., Ltd, a leading Chinese manufacturer of artificial hearts, has reportedly...

Company Drug

Hainan Poly Pharm Wins Health Canada Approval for Generic Cytovene-IV (Ganciclovir)

Fineline Cube Apr 17, 2023

Hainan Poly Pharm Co., Ltd (SHE: 300630), a China-based pharmaceutical company, has announced that it...

Company Deals

Zephyrm Bioscience Secures Over RMB 200 Million in Series B Financing for Stem-Cell Drug Development

Fineline Cube Apr 17, 2023

Zephyrm Bioscience, a prominent stem cell drug developer headquartered in Suzhou, has reportedly secured more...

Company Deals

Legend Biotech and Janssen Partner with Novartis on Carvykti Manufacturing and Clinical Supply

Fineline Cube Apr 17, 2023

Legend Biotech Corporation (NASDAQ: LEGN), a China-based biotech firm, and its US partner Janssen Pharmaceutical...

Company Drug

CanSino Biologics Receives NMPA Approval for Bivalent COVID-19 mRNA Vaccine

Fineline Cube Apr 17, 2023

CanSino Biologics Inc., a leading Chinese vaccines specialist, has announced that it has received clinical...

Company Drug

JS InnoPharm Initiates Phase Ib Study of AURKA Inhibitor VIC-1911 for EGFR-TKI Resistant NSCLC

Fineline Cube Apr 17, 2023

JS InnoPharm Ltd, a Shanghai-based pharmaceutical company, announced that the first patient has been dosed...

Company

Simcere Pharmaceutical Group Reports 26.4% YOY Revenue Growth in 2022 Financials

Fineline Cube Apr 17, 2023

Simcere Pharmaceutical Group (HKG: 2096), a China-based pharmaceutical company, has reported its financial results for...

Company

Henlius Reports 97.2% YOY Revenue Growth in Q1 2023, Highlighted by Strong Sales of Hanquyou and HaiSiZhuang

Fineline Cube Apr 17, 2023

China-based biopharmaceutical company Henlius (HKG: 2696) has released its financial report for the first quarter...

Policy / Regulatory

Hainan Introduces Management Regulations for Urgently Needed Import Drugs and Devices in Boao Lecheng

Fineline Cube Apr 17, 2023

The Hainan provincial government has issued a Notice on the Management Regulations for Clinically Urgently...

Company Drug

Minghui Pharmaceutical’s MH004 Cream Shows Positive Results in Atopic Dermatitis Phase II Trial

Fineline Cube Apr 17, 2023

China-based Minghui Pharmaceutical has unveiled positive top-line data from a Phase II trial of its...

Company Drug

AffaMed Therapeutics Gets NMPA Approval for Phase III Dextenza Study in Post-Ophthalmic Surgery

Fineline Cube Apr 17, 2023

China-based AffaMed Therapeutics has announced that it has received approval from the National Medical Products...

Medical Device Policy / Regulatory

NHC Proposes Updates to Access Standards for Class A and B Medical Equipment

Fineline Cube Apr 17, 2023

The National Healthcare Commission (NHC) has released two proposed updates to the Access Standards for...

Company Drug

Harbour Biomed to Present Early Clinical Data for CTLA-4 Antibody Combo at AACR 2023

Fineline Cube Apr 17, 2023

China-based Harbour Biomed (HKG: 2142) is set to release early clinical data for its CTLA-4...

Company Drug

RemeGen’s Disitamab Vedotin (RC48) Clears for Phase I Study in HER2-Positive Tumors

Fineline Cube Apr 14, 2023

RemeGen Ltd (HKG: 9995), a biopharmaceutical company, has announced that it has received approval from...

Company Drug

Junshi Biosciences’ JS401 Receives NMPA Approval for Hyperlipidemia Clinical Trial

Fineline Cube Apr 14, 2023

Junshi Biosciences (HKG: 1877, SHA: 688180), a leading China-based biopharmaceutical company, has announced that it...

Company Deals

Jiangxi Jemincare Group Secures Exclusive Rights to Promote MabPharm’s Biosimilar CMAB007

Fineline Cube Apr 14, 2023

Jiangxi Jemincare Group, a China-based healthcare company, has entered into a licensing agreement with fellow...

Company Deals Digital

Zhejiang Dian Diagnostics Partners with Meituan for Digital Healthcare Services Expansion

Fineline Cube Apr 14, 2023

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent medical diagnostics company based in China,...

Posts pagination

1 … 477 478 479 … 606

Recent updates

  • Novartis Secures Exclusive Rights to Zonsen PepLib’s Radioligand Asset
  • Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets
  • Johnson & Johnson Strikes Tariff Exemption Deal with Trump Administration
  • Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market
  • Merck in Talks to Acquire Revolution Medicines for $28‑32 Billion in Oncology Push
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Novartis Secures Exclusive Rights to Zonsen PepLib’s Radioligand Asset

Company Drug

Boan Biosimilar Prolia Wins Bolivia Approval, Targets Global Markets

Others

Johnson & Johnson Strikes Tariff Exemption Deal with Trump Administration

Company Deals

Hybio Pharmaceutical Licenses Semaglutide to Vitamedic for Brazil Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.